1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 11,100 | 11,400 | 20:37 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.01. | Devyser Diagnostics AB: Devyser publishes preliminary result for Q4 2024 | 572 | GlobeNewswire (Europe) | In light of this morning's communication that Fredrik Alpsten is leaving his position as CEO of Devyser and to avoid speculation, Devyser is releasing a summary of the year-end report for 2024 before... ► Artikel lesen | |
| 30.10.24 | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period July to September 2024 | 63 | GlobeNewswire (Europe) | "It is very gratifying to see the impact that we are having in the field of diagnostics. I have just returned from the ASHI event, a major transplantation conference in the US, and it is clear that... ► Artikel lesen | |
| 23.07.24 | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period April to June 2024 | 81 | GlobeNewswire (Europe) | "Devyser continued to report high sales growth in the second quarter. Organic growth compared with the same quarter of last year amounted to 41 percent in SEK. We won several large tenders during the... ► Artikel lesen | |
| 08.05.24 | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period January to March 2024 | 82 | GlobeNewswire (Europe) | "Devyser reports continued strong sales growth and high gross margins for the quarter. It is particularly pleasing to see that our investment in the Americas is continuing to produce results, with growth... ► Artikel lesen | |
| DEVYSER DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 20.02.24 | Devyser Diagnostics AB: Devyser Diagnostics publishes year-end report for January to December 2023 | 319 | GlobeNewswire (Europe) | "Devyser is able to report strong sales growth and record high gross margins for the fourth quarter. During the quarter, Devyser continued to demonstrate the competitiveness of its products by winning... ► Artikel lesen |
5 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDTRONIC | 85,77 | +0,07 % | Medtronic Appoints Thierry Pieton As CFO | WASHINGTON (dpa-AFX) - Medtronic Plc (MDT), a healthcare technology company, said on Tuesday that it has appointed Thierry Pieton as its Chief Financial Officer with effect from March 3. Pieton... ► Artikel lesen | |
| HCA HEALTHCARE | 298,40 | -3,68 % | ROUNDUP: HCA Healthcare Q4 Beats Market, Sees Growth In FY25; Declares Dividend | WASHINGTON (dpa-AFX) - HCA Healthcare, Inc. (HCA), while reporting weak fourth-quarter profit, but above market estimates, on Friday issued fiscal 2025 outlook, higher than last year, and announced... ► Artikel lesen | |
| LANTHEUS | 93,36 | -0,34 % | Radiopharm Theranostics: Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia | RAD to advance the clinical development of Lantheus innovative radiopharmaceuticals in Australia Initial collaboration will focus on a Phase 1 imaging trialFinancial incentives to be paid to RAD upon... ► Artikel lesen | |
| AMEDISYS | 87,50 | +0,57 % | Amedisys, Inc.: Amedisys Reports Third Quarter 2024 Financial Results | BATON ROUGE, La., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month periods ended September 30, 2024. Three-Month... ► Artikel lesen | |
| ENVISTA | 20,200 | -1,94 % | 5 Analysts Have This To Say About Envista Holdings | ||
| CAREDX | 21,510 | -4,36 % | Here's Why CareDx (CDNA) Traded Lower in Q4 | ||
| SYNEOS HEALTH | - | - | Research Solutions, Inc.: Research Solutions Reports Fiscal First Quarter 2025 Results | Reports 60% Increase in ARR to $17.6 Million, Positive Net Income and Cash Flow, Adjusted EBITDA of $1.3 Million HENDERSON, Nev., Nov. 14, 2024 /PRNewswire/ -- Research Solutions, Inc.... ► Artikel lesen | |
| GT BIOPHARMA | 2,440 | 0,00 % | GT Biopharma files for automatic mixed securities shelf | ||
| CARMAT | 1,074 | -0,92 % | CARMAT Announces Its Participation in Several Scientific and Investor Conferences During the 1st Half of 2025 | Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from... ► Artikel lesen | |
| CHEMOMETEC | 68,35 | +0,15 % | Chemometec A/S: Upgrade of revenue and operating profit guidance | ANNOUNCEMENT NO. 286 10 January 2025 Upgrade of revenue and operating profit guidance ChemoMetec sustained its positive performance in the second quarter of 2024/25 with better-than-expected sales... ► Artikel lesen | |
| HAMILTON THORNE | 1,490 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.12.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 02.12.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.12.2024ISIN NameCA81012R1064 SCOTTIE... ► Artikel lesen | |
| POLAREAN IMAGING | 0,001 | -94,12 % | Polarean Imaging plc: Appointment of Chase Hall, M.D., as Chief Medical Advisor | DURHAM, NC and LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging ("MRI") of the lungs, announces... ► Artikel lesen | |
| ARRAIL GROUP | 0,242 | 0,00 % | ARRAIL GROUP (06639): 2024/2025 INTERIM REPORT | ||
| FRESENIUS | 36,720 | -0,22 % | Leichte Zugewinne bei der Fresenius SE & Co. KGaA-Aktie (36,58 €) | Das Wertpapier von Fresenius SE & Co. KGaA notiert heute fester. Der jüngste Kurs betrug 36,58 Euro. Die Fresenius+Co KgaA-Aktie verzeichnet gegenwärtig einen Wertanstieg von 2,75 Prozent. Sie hat sich... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 53,48 | -1,58 % | Siemens Healthineers: Dieser Trading-Tipp war ein Treffer ohne Gewinn! | Im Express-Service hatten wir eine Short-Trade vorgeschlagen und das war der Hinweis für Abonneten: "Charttechnisch betrachtet bewegt sich der Kurs seit Ende Juli in einer breiten Seitwärtsbewegung... ► Artikel lesen |
Das Unternehmen DEVYSER DIAGNOSTICS AB kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 10,650 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DEVYSER DIAGNOSTICS AB finden Sie auf Wallstreet Online.
